Loading
A phase 2 trial of pembrolizumab, paclitaxel / nab-paclitaxel and bevacizumab in triple-negative breast cancer, run by Yukinori Ozaki, now recruiting.
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer is a phase 2, randomised interventional study registered as NCT06976944 by Yukinori Ozaki, with a registry enrolment figure of 24 participants, started 2025-06-24 and due to reach its primary completion in 2029-09. Interventions recorded: Pembrolizumab; Paclitaxel; Bevacizumab. Conditions listed: Recurrent Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Participants must have recurred after treatment with an anti-PD-1/PD-L1 antibody administered as monotherapy or in combination with other ICIs or chemotherapies as a perioperative drug therapy for triple negative breast cancer". Sites: Japan. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Bevacizumab, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Paclitaxel / nab-paclitaxel, Pembrolizumab and the tag tnbc-deep-dive.
Shares Triple-negative breast cancer trials open today (registry snapshot and UK sites), Paclitaxel / nab-paclitaxel, Pembrolizumab, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Triple-negative breast cancer trials open today (registry snapshot and UK sites), Paclitaxel / nab-paclitaxel, Pembrolizumab, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Triple-negative breast cancer trials open today (registry snapshot and UK sites), Paclitaxel / nab-paclitaxel, Pembrolizumab, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Triple-negative breast cancer trials open today (registry snapshot and UK sites), Paclitaxel / nab-paclitaxel, Pembrolizumab, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Bevacizumab, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/